“Per ELISA”: Time to adopt anti-transglutaminase/deamidated gliadin peptide diagnostic combination in coeliac disease of adults?
Digestive and Liver Disease · 2024
DOI: 10.1016/j.dld.2024.03.002 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Digestive and Liver Disease, 2024. Verfasst von Antonio Rispo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology, Department of Clinical Medicine and Surgery, Federico II University Hospital, Naples, Italy. Hauptthemen laut MEDLINE: Celiac Disease, Gliadin, Enzyme-Linked Immunosorbent Assay, Transglutaminases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Anti-endomysial antibodies (EMA) and anti-tissue transglutaminases (a-tTg) play a pivotal role in coeliac disease (CD) diagnosis. Deamidated anti-gliadin peptides (DGP) were added to the CD diagnostic workup. AIMS: We aimed to compare the diagnostic accuracies of ELISA-based (a-tTg/DGP) and immunofluorescence-ELISA-based strategies (EMA/a-tTg) for CD diagnosis. METHODS: From November 2020 to November 2022, we undertook an observational prospective study including consecutive adult patients with suspected CD. All subjects were tested for EMA, a-tTg and DGP IgA. An ROC curve was plotted to establish the best specificity cut-off of a-tTg and DGP levels, which would predict the presence of Marsh≥2 and Marsh=3. The diagnostic accuracies of a-tTg/DG and EMA/a-tTg were compared. RESULTS: The study included 275 CD patients. Histology showed Marsh=1 in 9.9%, Marsh=2 in 4.5%, and Marsh=3 in 85.6.%. The best cut-off value of a-tTg for predicting Marsh≥2 was 42 U/mL, while the best cut-off for predicting atrophy was 68.4 U/mL. The best cut-off value of DGP for predicting Marsh≥2 was 56 U/mL, while the best cut-off for predicting atrophy was 78 U/mL. A-tTg/EMA showed 97% sensitivity and 100% specificity, whereas a-tTg/DGP showed 94% sensitivity and 100% specificity. CONCLUSION: A-tTg/DGP is accurate for CD diagnosis and could reduce costs and operator-dependency of EMA. DGP, together with a-tTg, could replace EMA in CD diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology, Department of Clinical Medicine and Surgery, Federico II University Hospital, Naples, Italy.
- Gastroenterology, Department of Clinical Medicine and Surgery, Federico II University Hospital, Naples, Italy. Electronic address: giuliocalabrese94@gmail.com.
- Gastroenterology, "Santa Maria Delle Grazie" Hospital, Pozzuoli, Naples, Italy.
Zitieren
APA
Rispo, A., Calabrese, G., Toro, B., Olmo, O., Ricciolino, S., Cantisani, N. M., Limansky, L., Giaquinto, M., Caso, R., & Imperatore, N. (2024). “Per ELISA”: Time to adopt anti-transglutaminase/deamidated gliadin peptide diagnostic combination in coeliac disease of adults?. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2024.03.002
Vancouver
Rispo A, Calabrese G, Toro B, Olmo O, Ricciolino S, Cantisani NM, et al. “Per ELISA”: Time to adopt anti-transglutaminase/deamidated gliadin peptide diagnostic combination in coeliac disease of adults?. Digestive and Liver Disease. 2024. doi:10.1016/j.dld.2024.03.002
BibTeX
@article{Rispo2024,
author = {Rispo, Antonio and Calabrese, Giulio and Toro, Benedetta and Olmo, Oriana and Ricciolino, Simona and Cantisani, Nicola Mattia and Limansky, Lara and Giaquinto, Miriam and Caso, Rossella and Imperatore, Nicola},
title = {“Per ELISA”: Time to adopt anti-transglutaminase/deamidated gliadin peptide diagnostic combination in coeliac disease of adults?},
journal = {Digestive and Liver Disease},
year = {2024},
doi = {10.1016/j.dld.2024.03.002}
}
EUVIMED